CClinicalTrials.gg
RecruitingNCT05838144Updated Jul 18, 2023

Efficacy of Acapella on Spirometry Measures in Patients With Bronchiectasis

An interventional study of Acapella device and Only routine chest physical therapy program in Bronchiectasis, sponsored by South Valley University. Recruiting at 1 site in Egypt. Open to participants aged 40 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-18.

Sponsored by South Valley University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years ago, but the record still lists the study as recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years to 55 Years
Sex
All
01

Study summary

  1. Acapella group. Will use Acapella device for 3 times per day for 15 minutes for 7 days beside medications and routine chest physical therapy program .
  2. Only routine physical therapy program group ( control group). Will only take medications and routine chest physical therapy program.
Read the detailed description
  1. Acapella group.Will use Acapella device for 3 times per day for 15 minutes for 7 days beside medications and routine chest physical therapy program.
  2. Only routine physical therapy program group( control group). Will only take medications and routine chest physical therapy program Spirometer measures such as forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) will be measured for every patient before and after the end of 7 days.
02

Conditions studied

  • Bronchiectasis

Browse trials for

03

In context

Bronchiectasis

368 studies on the registry are indexed under Bronchiectasis; 104 are open to participants now.

This study's planned enrollment of 20 is below the median of 60 across 233 interventional studies indexed under Bronchiectasis.

Browse Bronchiectasis studies →

Lead sponsor

South Valley University is the lead sponsor of 147 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. bronchiectasis patients.
  2. Age range between 40 to 55 years old of both gender.
  3. Cooperative patients.

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe cardiac disorders.
  2. Un controlled hypertensive patients.
  3. Un controlled diabetic patients.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Acapella

    Will use Acapella device 3 times per day for 15 minutes for 7 days beside medications and routine physical therapy program.

    Device: Acapella device · Other: Only routine chest physical therapy program

  • Placebo comparator
    Only routine physical therapy program

    Only they will receive medications and routine physical therapy program.

    Other: Only routine chest physical therapy program

Interventions

  • DeviceAcapella device

    Group A. Will use Acapella device.

  • OtherOnly routine chest physical therapy program

    Group B. Will take medications and perform routine chest physical therapy program.

06

What researchers measure

Primary outcomes

  1. Spirometry measures

    FVC, FEV1

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
  • Shymaa yussuf abo zaid
    Cairo, Egypt
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05838144
Lead sponsor
South Valley University
Responsible party
Shymaa yussuf abo zaid (Lecturer, South Valley University) — Principal investigator
First posted
May 1, 2023
Start date
Aug 1, 2023 (estimated)
Primary completion
Sep 30, 2023 (estimated)
Completion
Oct 20, 2023 (estimated)
Last update
Jul 18, 2023

Study contacts

Shymaa Y Abo zaid
Contact
shaymaayoussef397@gmail.com
01010941685 ext. 01091631018
Shymaa Y Abo zaid
principal investigator · Lecturer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion